STOCK TITAN

TriSalus Life Sciences (TLSI) Stock Price, News & Analysis

TLSI NASDAQ
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
57 252 sessions, November 17, 2025 to November 17, 2026
Largest daily move
-41.4% close of May 13, 2026
1-year change
-48.8% closing prices, November 17, 2025 to November 17, 2026
1-month change
-36.8% closing prices, October 16, 2026 to November 17, 2026

Company Description

TriSalus Life Sciences, Inc. (Nasdaq: TLSI) is an oncology-focused medical technology company that concentrates on improving treatment for patients with solid tumors and other difficult-to-treat conditions. According to the company’s public disclosures, its platform combines proprietary drug delivery devices with standard-of-care therapies and a clinical-stage investigational immunotherapy, nelitolimod, a class C Toll-like receptor 9 (TLR9) agonist. TriSalus positions its technology to address challenges that limit the effectiveness of many existing therapies, particularly in liver, pancreatic and other solid tumor settings.

The company reports that its platform includes devices that utilize a proprietary Pressure-Enabled Drug Delivery™ (PEDD™) approach and an investigational immunotherapy. Multiple press releases describe TriSalus as a growing oncology-focused medical technology business that is also exploring applications in non-oncologic conditions where targeted embolization and drug delivery may be beneficial.

Pressure-Enabled Drug Delivery (PEDD) Technology

TriSalus states that its PEDD technology is a novel delivery approach designed to overcome anatomical and physiological barriers that can limit therapeutic delivery. Company materials explain that PEDD modulates pressure and flow during infusion in a way that is intended to deliver more therapeutic agent to the tumor while reducing undesired delivery to normal tissue. This approach is described as particularly relevant for organs such as the liver and pancreas, where high intratumoral pressure, collapsed vasculature and immunosuppressive tumor microenvironments can interfere with effective treatment.

In its descriptions of an “organ-specific platform,” TriSalus highlights two key obstacles it is designed to address: high intratumoral pressure caused by tumor growth and collapsed vasculature, and the immunosuppressive properties of liver and pancreatic tumor immune cells. By systematically targeting these barriers, the company aims to improve response to therapies and enable better patient outcomes.

TriSalus reports that it has developed FDA-cleared devices that incorporate its PEDD technology. Across multiple releases, the company describes the TriNav® Infusion System as a device for hepatic arterial infusion of liver tumors, and the TriNav Infusion System LV as a variant for hepatic arterial infusion of liver tumors as well. The company also cites a Pancreatic Retrograde Venous Infusion System for pancreatic tumors. These devices are described as using the PEDD approach to deliver a range of therapeutics directly to targeted tissue.

TriSalus also references the launch of TriNav® FLX, which it characterizes as an advancement in its PEDD-based portfolio designed to improve navigability in tortuous vessels. Company commentary notes that TriNav is used in liver embolization and that the PEDD approach is being evaluated in additional embolization applications, including thyroid artery embolization and uterine artery embolization, as described in clinical and key opinion leader event announcements.

Applications in Solid Tumors and Benign Disease

In its public statements, TriSalus consistently describes itself as focused on solid tumors, particularly in the liver and pancreas. The company also notes that its technology is being evaluated in other clinical settings. For example, TriSalus has highlighted investigator-published data on Pressure-Enabled Thyroid Artery Embolization (PED-TAE) using the TriNav Infusion System for symptomatic thyroid disease, including benign thyroid nodules and multinodular goiters. The company states that this minimally invasive technique targets the inferior thyroid arteries to reduce gland size and alleviate symptoms in patients who are not candidates for surgery or conventional therapies.

TriSalus has also announced a clinical trial evaluating genicular artery embolization (GAE) as a potential treatment for knee osteoarthritis, and has discussed the use of its PEDD approach in uterine artery embolization for uterine fibroids. In these communications, the company characterizes itself as bringing its drug delivery technology to both oncologic and non-oncologic conditions where embolization and targeted delivery may offer therapeutic benefit.

Nelitolimod Investigational Immunotherapy

Alongside its devices, TriSalus is developing nelitolimod, a clinical-stage investigational immunotherapeutic candidate described as a class C TLR9 agonist. Company materials state that nelitolimod is designed to treat or improve the immunosuppressive environment created by many tumors, which can render existing immunotherapies ineffective in organs such as the liver and pancreas. TriSalus reports that nelitolimod is being evaluated in Pressure-Enabled Regional Immuno-Oncology™ (PERIO) phase 1 clinical trials where it is delivered via PEDD technology.

The company notes that patient data generated during PERIO clinical trials support the hypothesis that nelitolimod delivered via PEDD may have favorable immune effects within the liver and systemically. It also emphasizes that TLR9, the target of nelitolimod, is expressed across cancer types and that the mechanical barriers addressed by PEDD are commonly present in solid tumors. TriSalus has indicated that it is in the final stages of data completion for several phase 1 trials and plans to explore partnership opportunities for further development.

Commercial Focus and Clinical Adoption

In recent financial updates, TriSalus has described “strong commercial performance” and “growing clinical adoption” of its TriNav product suite and PEDD platform across a broad range of solid tumor indications, with particular emphasis on liver-directed therapies. The company attributes revenue growth to increased use of TriNav in liver embolization and expansion into new embolization applications. It also notes that its commercial efforts are focused on the interventional radiology specialty and that it is investing in registry and other clinical programs to build a data-driven case for expanding PEDD technology into additional clinical settings.

TriSalus has characterized itself as working in partnership with leading cancer centers across the United States and as leveraging immuno-oncology expertise and technology development capabilities. These collaborations are described as supporting both the clinical evaluation of PEDD-based approaches and the broader adoption of its devices in practice.

Capital Structure, Exchange Offer and Emerging Growth Status

TriSalus identifies as an emerging growth company under U.S. securities regulations in multiple Form 8-K filings. In 2025, the company reported an exchange offer and consent solicitation related to its Series A Convertible Preferred Stock, along with a subsequent amendment to the certificate of designations and conversion of preferred shares into common stock. The company has also disclosed actions by its board and compensation committee, including adjustments to executive compensation and equity awards that are tied to achieving specified revenue levels over a defined period.

These filings, together with periodic earnings releases, provide insight into the company’s capital structure, financing strategy and governance decisions, but they do not alter the core description of TriSalus as an oncology-focused medical technology company built around PEDD devices and an investigational immunotherapy.

Position Within Biotechnology and Medical Technology

Within the broader biotechnology and medical technology landscape, TriSalus describes itself as operating at the intersection of drug delivery, interventional oncology and immuno-oncology. Its disclosures emphasize device-based delivery systems integrated with pharmacologic agents, rather than stand-alone therapeutics. The company’s focus on overcoming physical and immunologic barriers in solid tumors, particularly in the liver and pancreas, differentiates its stated approach from more generalized drug development strategies.

TriSalus’ communications consistently highlight its goal of improving therapeutic delivery and clinical outcomes by tailoring both the route and pressure of drug administration, and by pairing this with an immunotherapeutic designed to modify the tumor microenvironment. This combination of device technology and immunotherapy development defines the core of the company’s business model as presented in its public materials.

Stock Performance

$2.30
+1.10%
+0.02
Last updated: at
-48.8%
Performance 1 year
$141.6M

TriSalus Life Sciences (TLSI) closed at $2.30 on November 17, 2026. Over the past 12 months, the price has lost 48.8%.

See what a $1,000 investment in TLSI would be worth today

Average down calculator for TLSI

TLSI Metrics & Rankings

Price returns through November 17, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Latest News

TriSalus Life Sciences has 10 recent news articles, with the latest published on . Of the recent coverage, 6 articles coincided with positive price movement and 3 with negative movement. Key topics include earnings, conferences, earnings date, fda approval. View all TLSI news →

Insider Radar

Net Buyers
90-Day Summary
50,000
Shares Bought
1,481
Shares Sold
5
Transactions
Most Recent Transaction
Marshak Richard (Chief Commercial Officer) sold 544 shares @ $2.43 on November 16, 2026

Insider buying activity at TriSalus Life Sciences over the past 90 days may reflect management confidence in the company's direction. Institutional investors and analysts often monitor insider purchases as a potential bullish indicator for the stock.

Based on SEC Form 4 filings over the last 90 days.

Financial Highlights

TriSalus Life Sciences generated $45.2M in revenue in FY2025, retaining a 84.6% gross margin, operating income reached -$26.9M (-59.7% operating margin), and net income was -$39.2M, reflecting a -86.9% net profit margin. Diluted earnings per share stood at -$1.84. The company generated -$18.0M in operating cash flow. The current ratio was 2.80, measuring current assets divided by current liabilities.

$45.2M
Revenue (FY2025)
-$39.2M
Net Income (FY2025)
-$18.0M
Operating Cash Flow

Upcoming Events

DEC
01
December 1, 2026 - December 1, 2026 Marketing

One-on-one meetings

CEO Mary Szela and CFO David Patience to hold one-on-one investor meetings at Piper Sandler conference on Dec 1, 2026.
DEC
01
December 1, 2026 Marketing

Piper Sandler presentation

Management presentation at 38th Piper Sandler Healthcare Conference Dec 1 at 8:10am ET; webcast replay available 90 days on investor site.
JAN
01
January 1, 2027 Regulatory

Medicare reimbursement change

Medicare finalized higher hospital and national office-based reimbursement for pressure-enabled drug delivery, effective 2027-01-01.

TriSalus Life Sciences has 3 upcoming scheduled events. The next event, "One-on-one meetings", is scheduled for December 1, 2026 (in 14 days). Investors can track these dates to stay informed about potential catalysts that may affect the TLSI stock price.

Short Interest History

Last 12 Months

Short interest in TriSalus Life Sciences (TLSI) currently stands at 3.3 million shares, down 3.8% from the previous reporting period, representing 8.2% of the float. Since November 2025, short interest has increased by 339.0%.

Days to Cover History

Last 12 Months

Days to cover for TriSalus Life Sciences (TLSI) currently stands at 28.4 days, up 41.5% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has increased by 505.3%. Across the settlements charted above, it has ranged from 1.6 to 35.9 days.

TLSI Company Profile & Sector Positioning

TriSalus Life Sciences (TLSI) operates in the Medical Devices industry within the broader Healthcare sector and is listed on the NASDAQ.

Investors comparing TLSI often look at related companies in the same sector, including Inogen Inc (INGN), Neuronetics, Inc. (STIM), Quanterix Corporation (QTRX), Perspective Therapeutics, Inc. (CATX), and Pulmonx Corporation (LUNG). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate TLSI's relative position within its industry.

Frequently Asked Questions

The current stock price of TriSalus Life Sciences (TLSI) is $2.30 as of November 17, 2026.

The market cap of TriSalus Life Sciences (TLSI) is approximately $141.6M. Learn more about what market capitalization means .

The FY2025 revenue of TriSalus Life Sciences (TLSI) is $45.2M, from its most recent completed fiscal year.

The FY2025 net income of TriSalus Life Sciences (TLSI) is -$39.2M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of TriSalus Life Sciences (TLSI) is -$1.84 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of TriSalus Life Sciences (TLSI) is -$18.0M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The net profit margin of TriSalus Life Sciences (TLSI) is -86.9% for FY2025, its most recent completed fiscal year. Learn about profit margins.

The operating profit margin of TriSalus Life Sciences (TLSI) is -59.7% for FY2025, its most recent completed fiscal year. Learn about operating margins.

The gross profit margin of TriSalus Life Sciences (TLSI) is 84.6% for FY2025, its most recent completed fiscal year. Learn about gross margins.

The current ratio of TriSalus Life Sciences (TLSI), current assets divided by current liabilities, was 2.80 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The gross profit of TriSalus Life Sciences (TLSI) is $38.2M for FY2025, its most recent completed fiscal year.

The operating income of TriSalus Life Sciences (TLSI) is -$26.9M for FY2025, its most recent completed fiscal year. Learn about operating income.

TriSalus Life Sciences, Inc. is described in its public disclosures as an oncology-focused medical technology company. It develops and commercializes devices that use its proprietary Pressure-Enabled Drug Delivery (PEDD) technology and is advancing an investigational immunotherapeutic, nelitolimod, to improve treatment for patients with solid tumors and certain non-oncologic conditions.

TriSalus’s core technology is its proprietary Pressure-Enabled Drug Delivery (PEDD) approach. The company states that PEDD modulates pressure and flow during infusion to deliver more therapeutic agent to the tumor while reducing undesired delivery to normal tissue, addressing anatomical and physiological barriers that can limit treatment effectiveness.

Company materials describe three FDA-cleared devices that use the PEDD approach: the TriNav Infusion System and TriNav Infusion System LV for hepatic arterial infusion of liver tumors, and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. TriSalus has also announced TriNav FLX as an advancement in its PEDD-based portfolio.

Nelitolimod is a clinical-stage investigational immunotherapy that TriSalus identifies as a class C Toll-like receptor 9 (TLR9) agonist. The company states that nelitolimod is designed to address the immunosuppressive environment created by many tumors, particularly in the liver and pancreas, and is being evaluated in PERIO phase 1 clinical trials where it is delivered using the PEDD technology.

TriSalus emphasizes applications in solid tumors, especially liver and pancreatic tumors. Its public communications also describe work in benign thyroid disease through pressure-enabled thyroid artery embolization, uterine fibroids via uterine artery embolization, and knee osteoarthritis through genicular artery embolization, reflecting both oncologic and non-oncologic uses of its PEDD platform.

The company explains that PEDD is designed to address high intratumoral pressure, collapsed vasculature and immunosuppressive tumor microenvironments that can restrict therapeutic delivery. By modulating pressure and flow, PEDD aims to deliver more therapeutic agent to the tumor and reduce exposure of normal tissue, with the goal of improving patient outcomes.

TriNav is described as an infusion system that incorporates TriSalus’s PEDD technology. Company disclosures state that TriNav and TriNav LV are used for hepatic arterial infusion of liver tumors and that TriNav is employed in liver embolization and is being evaluated in additional embolization applications, such as thyroid artery embolization and uterine artery embolization.

TriSalus reports that it partners with leading cancer centers across the United States and collaborates with interventional radiologists and other specialists. These partnerships support clinical trials, registry studies and evaluations of new embolization applications for its PEDD-based devices, such as the PROTECT registry for thyroid artery embolization.

In its press releases and SEC filings, the company identifies itself as TriSalus Life Sciences, Inc. trading on Nasdaq under the ticker symbol TLSI.

In recent earnings-related press releases, TriSalus has reported revenue growth associated with increased use of its TriNav system and PEDD platform in liver-directed therapies and other applications. The company links this growth to expanding clinical adoption and commercial momentum, while noting ongoing investment in clinical data and platform expansion.